Moreover, salsalate, a prodrug of salicylate, could diminish p300 acetyltransferase activity, acetylated-Tau (lysine 174) level, and Tau-mediated cognitive impairment in PS19 transgenic mice model of frontotemporal dementia (FTD), confirming that the inhibition of Tau acetylation is a promising therapeutic target for Tau pathology in AD (Min et al. 2015) (Fig. 2). Here, MAPT is linked to Cognitive impairment.